This webinar will discuss key considerations for instrument selection, data quality assurance and innovative enabling technologies for evaluating Parkinsonian symptoms.
People with Parkinson’s disease or parkinsonian conditions suffer from a range of symptoms, the most apparent of which may be motor impairment. However, efforts to explore meaningfulness to patients have resulted in recent drug development efforts also seeking to address non-motor symptoms. In Parkinson’s Disease, Parkinson’s disease Dementia (PDD) and Parkinsonian disorders such as Multiple System Atrophy (MSA), Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD) and Dementia with Lewy Bodies (DLB), it is important to evaluate the impact of a range of Parkinsonian symptom domains — including cognitive or behavioral impairment — and to understand how these may relate to motor symptoms.
To better answer important questions about the safety and efficacy of therapeutic candidates for people with Parkinson’s disease and atypical Parkinsonian disorders, fit-for-purpose assessments are critical to evaluate the full range of symptom domains to gather a complete picture of an individual’s condition.
In this webinar, hear from Clario and Cogstate scientists as they offer guidance on effective digital and conventional assessment options, tactics to improve the quality of data via strategic rater training and monitoring and describe how to leverage precision motion sensor technology to discover meaningful and functional insights on patient motor function.
The webinar will also include regulatory considerations, such as acceptance, recent digital health technology guidance and approval pathway selection for clinical outcome assessments or biomarker endpoints.
Join this webinar to learn how digital assessments and enabling technologies help gain a comprehensive understanding of Parkinsonian symptoms, reflective of importance to patients, across motor, cognitive & behavioral impairments.
Chris Edgar, PhD, Chief Science Officer, Cogstate
Dr. Chris Edgar is an experienced leader in cognitive assessment and clinical endpoint strategy who provides expert guidance to Cogstate’s pharmaceutical customers throughout all stages of trial conduct, from study design and test selection through final analysis. Prior to joining Cogstate as Senior Vice President, Clinical Science in 2018, Dr. Edgar oversaw clinical endpoint strategy for multiple neuroscience indications in the Patient-Centered Outcomes Research group at Roche. Dr. Edgar has held other key industry positions including Principal Scientist at Roche, Senior Clinical Lead at Bracket/UBC and Scientific Director at Cognitive Drug Research Ltd. He holds a PhD in psychopharmacology from Northumbria University and has 20 years of pharmaceutical industry experience.
Lisle Kingery, PhD, Senior Principal Scientist, Cogstate
Lisle Kingery, PhD is a clinical neuropsychologist with over 20 years’ clinical and research experience in Alzheimer’s and Parkinson’s disease clinical trials. His areas of expertise include neuropsychological test training and central monitoring of rater and scale data in global clinical trials. He has directed numerous rater training and central monitoring programs in Alzheimer’s disease, Parkinson’s disease and other CNS indications. He has evaluated and trained raters globally at dozens of clinical trial investigator meetings. Dr. Kingery also has significant experience producing training videos for neuropsychological tests and for the assessment of Parkinson’s disease and other movement disorders.
Kristen Sowalsky, DC, PhD, VP Medical & Scientific Affairs, Precision Motion, Clario
Dr. Kristen Sowalsky leads the scientific consulting services team for Precision Motion at Clario. With an advanced background in applied neuromechanics, kinesiology and exercise science, including six years as a provider in clinical practice, she consults with clinicians, researchers and product technologists providing scientific evidence and advice to sponsors and CROs on meeting clinical trial study objectives. Dr. Sowalsky’s academic achievements include a BS in kinesiology and exercise science from Appalachian State University, Doctor of Chiropractic from Logan University and a PhD in applied neuromechanics, from the University of Florida. Passionate about improving the lives of patients and their families, Dr. Sowalsky continues to build the body of evidence for precision motion monitoring measures of PerfO to capture clinically meaningful digital mobility outcomes to inform therapeutic innovation and development.
Who Should Attend?
Executives, directors, scientists and managers from pharma, biotech and CROs responsible for clinical development of hybrid or decentralized clinical trial solutions, in central nervous system (CNS) studies, including:
- Research and Development
- Clinical Operations
- Clinical Science
- Outcomes Research
- Outsourcing and Procurement
- Project Management
- Clinical Trial Planning and Optimization
- Medical Affairs
What You Will Learn
Attendees will learn:
- How to select and manage fit-for-purpose digital and conventional assessment options
- Options to improve the quality of data captured via strategic rater training and monitoring
- How to leverage precision motion sensor technology to discover meaningful and functional insights on patient motor function
Cogstate Ltd (ASX:CGS) is a leading science and technology solutions provider dedicated to optimizing the measurement of cognition in clinical trials, academic research and healthcare. Cogstate provides enabling technologies and professional services for higher quality neuropsychological assessments and is a pioneer in commercializing rapid, reliable and highly sensitive computerized cognitive tests. Cogstate customers include the world’s leading biopharmaceutical companies; elite sporting organizations and military; physicians and patients; renowned academic institutions and public-private partnerships. For more information, please visit www.cogstate.com.